Source: Lancet rheumatology. Unidade: FM
Subjects: IMUNOGENÉTICA, COVID-19, SISTEMA IMUNE, IMUNOGENICIDADE DA VACINA
ABNT
AIKAWA, Nadia E et al. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. Lancet rheumatology, v. 4, n. 2, p. E113-E124, 2022Tradução . . Disponível em: https://doi.org/10.1016/S2665-9913(21)00327-1. Acesso em: 09 set. 2024.APA
Aikawa, N. E., Kupa, L. de V. K., Pasoto, S. G., Shinjo, S. K., Pereira, R. M. R., Sartori, A. M. C., et al. (2022). Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. Lancet rheumatology, 4( 2), E113-E124. doi:10.1016/S2665-9913(21)00327-1NLM
Aikawa NE, Kupa L de VK, Pasoto SG, Shinjo SK, Pereira RMR, Sartori AMC, Duarte AJ da S, Antonangelo L, Sabino EC, Menezes PR, Kallas EG, Silva CAA da, Bonfa ESD de O. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study [Internet]. Lancet rheumatology. 2022 ; 4( 2): E113-E124.[citado 2024 set. 09 ] Available from: https://doi.org/10.1016/S2665-9913(21)00327-1Vancouver
Aikawa NE, Kupa L de VK, Pasoto SG, Shinjo SK, Pereira RMR, Sartori AMC, Duarte AJ da S, Antonangelo L, Sabino EC, Menezes PR, Kallas EG, Silva CAA da, Bonfa ESD de O. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study [Internet]. Lancet rheumatology. 2022 ; 4( 2): E113-E124.[citado 2024 set. 09 ] Available from: https://doi.org/10.1016/S2665-9913(21)00327-1